Zobrazeno 1 - 10
of 20
pro vyhledávání: '"G. Capellá"'
Autor:
Terradas M; Hereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Schubert SA; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Viana-Errasti J; Hereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Ruano D; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Aiza G; Hereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Nielsen M; Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands., Marciel P; Hereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Tops CM; Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands., Parra G; CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain., Morreau H; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Torrents D; Life Sciences Department, Barcelona Supercomputing Centre (BSC), Barcelona, Spain.; ICREA, Barcelona, Spain., van Leerdam ME; Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Capellá G; Hereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., de Miranda NFCC; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands., Valle L; Hereditary Cancer Programme, Catalan Institute of Oncology; Oncobell Programme, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@idibell.cat.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. lvalle@idibell.cat., van Wezel T; Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands. t.van_wezel@lumc.nl.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. t.van_wezel@lumc.nl.
Publikováno v:
European journal of human genetics : EJHG [Eur J Hum Genet] 2024 Jul; Vol. 32 (7), pp. 871-875. Date of Electronic Publication: 2024 May 22.
Autor:
Marín F; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; CIBER Oncología (CIBERONC), Instituto Salud Carlos III, Madrid, Spain., Canet-Hermida J; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; CIBER Oncología (CIBERONC), Instituto Salud Carlos III, Madrid, Spain., Bianchi V; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada., Chung J; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada., Wimmer K; Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria., Foulkes W; Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.; Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada., Pérez-Alonso V; Department of Pediatric Hematology and Oncology, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain., Domínguez-Pinilla N; Department of Pediatric Hematology and Oncology, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain., Sábado C; Department of Pediatric Hematology and Oncology, Hospital Vall d'Hebron, Barcelona, Spain., Vázquez-Gómez F; Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain., Molinés A; Hematology and Hemotherapy Unit, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain., Fioravantti V; Department of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain., Carrasco E; Hereditary Cancer Genetics Group, Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Stengs L; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada., Edwards M; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada., Negm L; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.; Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada., Das A; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.; Department of Pediatrics, University of Toronto, Toronto, ON, Canada., Aronson M; Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON, Canada., Pastor Á; Laboratorio de Cáncer Hereditario, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 Octubre (i+12), Madrid, Spain., Rueda D; Laboratorio de Cáncer Hereditario, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 Octubre (i+12), Madrid, Spain., González-Granado LI; Immunodeficiencies Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre, Research Institute Hospital 12 Octubre (i+12), Madrid, Spain., Tabori U; The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada.; Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.; Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada., Capellá G; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; CIBER Oncología (CIBERONC), Instituto Salud Carlos III, Madrid, Spain.; Hereditary Cancer Program, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Pineda M; Hereditary Cancer Group, Molecular Mechanisms and Experimental Therapy in Oncology Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; CIBER Oncología (CIBERONC), Instituto Salud Carlos III, Madrid, Spain.; Hereditary Cancer Program, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Publikováno v:
Clinical chemistry [Clin Chem] 2024 May 02; Vol. 70 (5), pp. 737-746.
Autor:
Rofes P; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., González S; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Navarro M; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hereditary Cancer Program, Program for Predictive and Personalized Medicine of Cancer-Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain., Moreno-Cabrera JM; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hereditary Cancer Program, Program for Predictive and Personalized Medicine of Cancer-Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain., Solanes A; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Hereditary Cancer Program, Program for Predictive and Personalized Medicine of Cancer-Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain., Darder E; Hereditary Cancer Program, Catalan Institute of Oncology, Girona Institute for Biomedical Research (IDIBGi), Girona, Spain., Carrasco E; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Iglesias S; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain., Salinas M; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain., Gómez C; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain., Velasco À; Hereditary Cancer Program, Catalan Institute of Oncology, Girona Institute for Biomedical Research (IDIBGi), Girona, Spain., Tuset N; Medical Oncology Department, Arnau de Vilanova University Hospital, Lleida, Spain., Varela M; Department of Pathology, Bellvitge University Hospital, Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain., Llort G; Medical Oncology Department, Parc Taulí University Hospital, Sabadell, Spain., Ramon Y Cajal T; Medical Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain., Grau È; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Hereditary Cancer Program, Program for Predictive and Personalized Medicine of Cancer-Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain., Dueñas N; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., de la Ossa Merlano N; Department of Pathology, General University Hospital of Catalonia, QuironSalud Group, Sant Cugat del Vallès, Spain., Matías-Guiu X; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department of Pathology, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona, Spain; Department of Pathology, Arnau de Vilanova University Hospital, Lleida Institute for Biomedical Research (IRBLleida), University of Lleida, Lleida, Spain., Rivera B; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada., Balmaña J; Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Pineda M; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Brunet J; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hereditary Cancer Program, Catalan Institute of Oncology, Girona Institute for Biomedical Research (IDIBGi), Girona, Spain., Capellá G; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Del Valle J; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Lázaro C; Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Electronic address: clazaro@iconcologia.net.
Publikováno v:
The Journal of molecular diagnostics : JMD [J Mol Diagn] 2021 Nov; Vol. 23 (11), pp. 1452-1459. Date of Electronic Publication: 2021 Aug 25.
Autor:
Belhadj S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Moutinho C; Cancer Epigenetics and Biology Program (PEBC), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Setien F; Cancer Epigenetics and Biology Program (PEBC), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Llinàs-Arias P; Cancer Epigenetics and Biology Program (PEBC), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Pérez-Salvia M; Cancer Epigenetics and Biology Program (PEBC), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Pons T; Department of Immunology and Oncology, National Center for Biotechnology, Spanish National Research Council (CNB-CSIC), Madrid, Spain., Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain., Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain., Esteller M; Cancer Epigenetics and Biology Program (PEBC), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain. Electronic address: mesteller@idibell.cat., Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain. Electronic address: lvalle@iconcologia.net.
Publikováno v:
Cancer letters [Cancer Lett] 2019 Apr 10; Vol. 447, pp. 86-92. Date of Electronic Publication: 2019 Jan 21.
Autor:
Grolleman JE; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., de Voer RM; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands. Electronic address: richarda.devoer@radboudumc.nl., Elsayed FA; Department of Pathology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., Nielsen M; Department of Clinical Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., Weren RDA; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Palles C; Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Ligtenberg MJL; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Vos JR; Department of Human Genetics, Radboud Institute for Health Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Ten Broeke SW; Department of Clinical Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., de Miranda NFCC; Department of Pathology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., Kuiper RA; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Kamping EJ; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Jansen EAM; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Vink-Börger ME; Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Popp I; Department of Human Genetics, University of Würzburg, 97074 Würzburg, Germany., Lang A; Vorarlberg Cancer Registry, Agency for Preventive and Social Medicine, Bregenz 6900, Austria., Spier I; Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany; Center for Hereditary Tumor Syndromes, University of Bonn, 53127 Bonn, Germany., Hüneburg R; Center for Hereditary Tumor Syndromes, University of Bonn, 53127 Bonn, Germany; Department of Internal Medicine I, University of Bonn, 53127 Bonn, Germany., James PA; Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbournem, VIC 3000, Australia., Li N; Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia., Staninova M; Center for Biomolecular Pharmaceutical Analyzes, UKIM Faculty of Pharmacy, 1000 Skopje, Republic of Macedonia., Lindsay H; Leeds Genetics Laboratory, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK., Cockburn D; Leeds Genetics Laboratory, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK., Spasic-Boskovic O; East Anglian Medical Genetics Service, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK., Clendenning M; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC 3010, Australia., Sweet K; Division of Human Genetics, Ohio State University Medical Centre, Columbus, OH 43221, USA., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Barcelona 08908, Spain., Sjursen W; Department of Medical Genetics, St Olavs University Hospital, 7030 Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway., Høberg-Vetti H; Western Norway Familial Cancer Center, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, 5021 Bergen, Norway., Jongmans MC; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Neveling K; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Geurts van Kessel A; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Morreau H; Department of Pathology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., Hes FJ; Department of Clinical Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., Sijmons RH; Department of Genetics, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands., Schackert HK; Department of Surgical Research, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany., Ruiz-Ponte C; Fundación Pública Galega de Medicina Xenómica (FPGMX)-SERGAS, Grupo de Medicina Xenómica-USC, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia 15706, Spain., Dymerska D; Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland., Lubinski J; Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland., Rivera B; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada., Foulkes WD; Department of Human Genetics, McGill University, Montreal, QC H3A 0C7, Canada., Tomlinson IP; Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK; Oxford National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK., Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Barcelona 08908, Spain., Buchanan DD; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC 3010, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, VIC 3010, Australia; Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC 3010, Australia., Kenwrick S; East Anglian Medical Genetics Service, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK., Adlard J; Yorkshire Regional Genetics Service and University of Leeds, Leeds LS7 4SA, UK., Dimovski AJ; Center for Biomolecular Pharmaceutical Analyzes, UKIM Faculty of Pharmacy, 1000 Skopje, Republic of Macedonia., Campbell IG; Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3000, Australia., Aretz S; Institute of Human Genetics, University of Bonn, 53127 Bonn, Germany; Center for Hereditary Tumor Syndromes, University of Bonn, 53127 Bonn, Germany., Schindler D; Department of Human Genetics, University of Würzburg, 97074 Würzburg, Germany., van Wezel T; Department of Pathology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands., Hoogerbrugge N; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands., Kuiper RP; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; Princess Máxima Center for Pediatric Oncology, 3584 CT Utrecht, The Netherlands. Electronic address: r.kuiper@prinsesmaximacentrum.nl.
Publikováno v:
Cancer cell [Cancer Cell] 2019 Feb 11; Vol. 35 (2), pp. 256-266.e5.
Autor:
Castellsagué E; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.; Department of Medical Genetics, The Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.; Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain., Li R; McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada., Aligue R; Biomedical Sciences Department, School of Medicine, University de Barcelona, IDIBAPS, Barcelona, Spain., González S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain., Sanz J; Genetic Counselling Unit, Hospital Universitari de Vic, Barcelona, Spain., Martin E; Biomedical Sciences Department, School of Medicine, University de Barcelona, IDIBAPS, Barcelona, Spain., Velasco À; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain., Stewart CJR; Department of Histopathology, King Edward Memorial Hospital, and School for Women's and Infants' Health, University of Western Australia, Perth, Australia., Vidal A; Department of Pathology, Hospital de Bellvitge, CIBERONC, Barcelona, Spain., Majewski J; McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada., Rivera B; Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.; Department of Medical Genetics and Cancer Research Program, Research Institute McGill University Health Centre, Montreal, Quebec, Canada., Polak P; Icahn School of Medicine at Mount Sinai, Department of Oncological Sciences, Mount Sinai Hospital, New York City, New York., Matias-Guiu X; Department of Pathology, Hospital de Bellvitge, CIBERONC, Barcelona, Spain., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGI, Girona, Spain.; Medical Sciences Department, School of Medicine, University of Girona, Girona, Spain., Foulkes WD; Department of Human Genetics, McGill University, Montreal, Quebec, Canada.; Department of Medical Genetics, The Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.; Department of Medical Genetics and Cancer Research Program, Research Institute McGill University Health Centre, Montreal, Quebec, Canada.; Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada.
Publikováno v:
Human mutation [Hum Mutat] 2019 Jan; Vol. 40 (1), pp. 36-41. Date of Electronic Publication: 2018 Nov 20.
Autor:
Quintana I; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Mejías-Luque R; Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.; German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany., Terradas M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Piñol V; Digestive Unit, Hospital Universitario de Girona Dr Josep Trueta, Girona, Spain.; School of Medicine, University of Girona, Girona, Spain., Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Belhadj S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Grau E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Darder E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain., Solanes A; Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, Spain., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Gerhard M; Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, Munich, Germany.; German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany., Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Publikováno v:
Gut [Gut] 2018 Dec; Vol. 67 (12), pp. 2230-2232. Date of Electronic Publication: 2018 Jan 12.
Autor:
Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain., De Voer RM; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Hubrecht Institute - KNAW (Royal Netherlands Academy of Arts and Sciences), Utrecht, The Netherlands., Olivera-Salguero R; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain., Rodríguez-Perales S; Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Pons T; Structural Biology and Biocomputing Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.; Department of Immunology and Oncology, National Centre for Biotechnology (CNB-CSIC), Madrid, Spain., Setién F; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain., Aiza G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain., Valdés-Mas R; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain.; Department of Biochemistry and Molecular Biology, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo and CIBERONC, Oviedo, Spain., Bertini A; Molecular Cytogenetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain., Vreede L; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain., Iglesias S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain., González S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain., Valencia A; Life Science Department, Barcelona Supercomputing Centre (BSC-CNS), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Esteller M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain.; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain., Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain., Kops GJPL; Hubrecht Institute - KNAW (Royal Netherlands Academy of Arts and Sciences), Utrecht, The Netherlands., Urioste M; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO) and Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Puente XS; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain.; Department of Biochemistry and Molecular Biology, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo and CIBERONC, Oviedo, Spain., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain., Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Av. Gran Via 199-203, 08908, Barcelona, Spain. lvalle@iconcologia.net.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain. lvalle@iconcologia.net.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain. lvalle@iconcologia.net.
Publikováno v:
Molecular cancer [Mol Cancer] 2018 Feb 15; Vol. 17 (1), pp. 23. Date of Electronic Publication: 2018 Feb 15.
Autor:
Bellido F; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Sowada N; Institute of Human Genetics, University of Ulm, Ulm, Germany., Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Pons T; Structural Biology and Biocomputing Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Valdés-Mas R; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain., Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Aiza G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Iglesias S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Soto JL; Molecular Genetics Laboratory, Elche University Hospital, Elche, Spain; Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain., Urioste M; Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO) and Center for Biomedical Network Research on Rare Diseases, Madrid, Spain., Caldés T; Laboratorio de Oncología Molecular, Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain., Balbín M; Laboratorio de Oncología Molecular, Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain., Blay P; Familial Cancer Unit, Department of Medical Oncology, Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, Oviedo, Spain., Rueda D; Molecular Biology Laboratory, 12 de Octubre University Hospital, Madrid, Spain., Durán M; Instituto de Biología y Genética Molecular, IBGM-UVA-CSIC, Valladolid, Spain., Valencia A; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Life Science Department, Barcelona; Supercomputing Centre (BSC-CNS), Barcelona, Spain., Moreno V; Unit of Biomarkers and Susceptibility, Catalan Institute of Oncology, IDIBELL and CIBERESP, Hospitalet de Llobregat, Spain; Department of Clinical Sciences, School of Medicine, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBGi, Girona, Spain., Blanco I; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Calin GA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Borck G; Institute of Human Genetics, University of Ulm, Ulm, Germany., Puente XS; Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, Oviedo, Spain., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Valle L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de Llobregat, Barcelona, Spain. Electronic address: lvalle@iconcologia.net.
Publikováno v:
Gastroenterology [Gastroenterology] 2018 Jan; Vol. 154 (1), pp. 181-194.e20. Date of Electronic Publication: 2017 Sep 12.
Autor:
Vargas-Parra GM; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., González-Acosta M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Thompson BA; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT.; Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Australia., Gómez C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Fernández A; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Dámaso E; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Pons T; Structural Biology and Biocomputing Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Morak M; Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Ziemssenstr. Germany MGZ-Medizinisch Genetisches Zentrum, Munich, Germany.; MGZ-Medizinisch Genetisches Zentrum, Munich, Germany., Del Valle J; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Iglesias S; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Velasco À; Hereditary Cancer Program, Catalan Institute of Oncology, IdIBGI, Girona, Spain., Solanes A; Hereditary Cancer Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain., Sanjuan X; Pathology Department, Hospital Universitari de Bellvitge-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., Padilla N; Research Unit in Translational Bioinformatics, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., de la Cruz X; Research Unit in Translational Bioinformatics, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Valencia A; Structural Biology and Biocomputing Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain., Holinski-Feder E; Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Ziemssenstr. Germany MGZ-Medizinisch Genetisches Zentrum, Munich, Germany.; MGZ-Medizinisch Genetisches Zentrum, Munich, Germany., Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, IdIBGI, Girona, Spain., Feliubadaló L; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain.; Hereditary Cancer Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain., Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, CIBERONC, Hospitalet de Llobregat, Spain.
Publikováno v:
International journal of cancer [Int J Cancer] 2017 Oct 01; Vol. 141 (7), pp. 1365-1380. Date of Electronic Publication: 2017 Jul 03.